ATAI LIFE SCIENCES
ATAI is a global biotech company builder that leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering from mental health disorders. The company is committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space. ATAI Life Sciences was founded in 2018 and is based in Munich, Bayern, Germany.
ATAI LIFE SCIENCES
Industry:
Biotechnology Health Care Life Science Mental Health Therapeutics
Founded:
2018-01-01
Status:
Active
Contact:
+49 (0) 89 2153 9035
Total Funding:
522.1 M USD
Technology used in webpage:
IPv6 Person Schema Facebook Sharer Gravatar Profiles U.S. Server Location Pinterest Akamai Hosted WordPress 5.9
Similar Organizations
Bright Peak Therapeutics
Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases.
Carisma Therapeutics
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
COMPASS Pathways
Compass Pathways is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health.
Garuda Therapeutics
Garuda Therapeutics is developing off-the-shelf hematopoietic stem cell (HSC) therapies to treat severe and life-threatening diseases.
Tmunity Therapeutics
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells
Verismo Therapeutics
Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer.
Current Employees Featured
Lars Christian Wilde Co-Founder @ ATAI Life Sciences
Co-Founder
2018-11-01
Florian Brand CEO and Co-Founder @ ATAI Life Sciences
CEO and Co-Founder
2018-06-01
Matthias Luz Chief Medical Officer @ ATAI Life Sciences
Chief Medical Officer
Srinivas Rao Co-Founder & Chief Scientific Officer @ ATAI Life Sciences
Co-Founder & Chief Scientific Officer
2019-04-01
Christian Angermayer Founder @ ATAI Life Sciences
Founder
Sean Trigony Investor @ ATAI Life Sciences
Investor
2019-08-01
Frank Stegert VP, Investment, Management, and Operations @ ATAI Life Sciences
VP, Investment, Management, and Operations
2020-09-01
David Keene VP of Digital Therapeutics @ ATAI Life Sciences
VP of Digital Therapeutics
2020-05-01
Gregory T. Bates Regulatory Affairs Consultant @ ATAI Life Sciences
Regulatory Affairs Consultant
2022-05-01
Steven Bartlett Investor @ ATAI Life Sciences
Investor
2020-11-01
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-04-07 | Psyber | Psyber acquired by ATAI Life Sciences | N/A |
| 2021-01-12 | Recognify Life Sciences | Recognify Life Sciences acquired by ATAI Life Sciences | N/A |
| 2019-01-03 | Perception Neuroscience | Perception Neuroscience acquired by ATAI Life Sciences | N/A |
Investors List
Hercules Capital
Hercules Capital investment in Post-IPO Debt - ATAI Life Sciences
GrayBella Capital
GrayBella Capital investment in Convertible Note - ATAI Life Sciences
Talent Resources Ventures
Talent Resources Ventures investment in Funding Round - ATAI Life Sciences
Infinitas Capital
Infinitas Capital investment in Series D - ATAI Life Sciences
What If Ventures
What If Ventures investment in Series D - ATAI Life Sciences
Alpha Wave Global
Alpha Wave Global investment in Series D - ATAI Life Sciences
Arda Kara
Arda Kara investment in Series D - ATAI Life Sciences
Subversive Capital
Subversive Capital investment in Series D - ATAI Life Sciences
Presight Capital
Presight Capital investment in Series D - ATAI Life Sciences
Korify Capital
Korify Capital investment in Series D - ATAI Life Sciences
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2024-01-04 | Beckley Psytech | ATAI Life Sciences investment in Corporate Round - Beckley Psytech | 40 M USD |
| 2024-01-04 | Beckley Psytech | ATAI Life Sciences investment in Secondary Market - Beckley Psytech | 10 M USD |
| 2023-08-31 | IntelGenX | ATAI Life Sciences investment in Post-IPO Equity - IntelGenX | 3 M CAD |
| 2023-01-09 | IntelGenX | ATAI Life Sciences investment in Post-IPO Debt - IntelGenX | 3 M USD |
| 2022-02-01 | IntelGenX | ATAI Life Sciences investment in Post-IPO Debt - IntelGenX | 3 M USD |
| 2021-03-15 | IntelGenX | ATAI Life Sciences investment in Post-IPO Equity - IntelGenX | 12.35 M USD |
| 2021-03-15 | IntelGenX | ATAI Life Sciences investment in Post-IPO Debt - IntelGenX | 2 M USD |
| 2020-04-27 | COMPASS Pathways | ATAI Life Sciences investment in Series B - COMPASS Pathways | 80 M USD |
| 2019-04-24 | Innoplexus | ATAI Life Sciences investment in Series C - Innoplexus | N/A |
Key Employee Changes
| Date | New article |
|---|---|
| 2024-02-06 | Atai Life Sciences Names Anne Johnson CFO |
More informations about "ATAI Life Sciences"
Home - atai Life Sciences
Atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates. Press releases . atai Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit. Press releases . atai Life Sciences to … See details»
atai Life Sciences - Wikipedia
In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. [1] [7] In January 2023, atai Life Science's leading drug … See details»
atai Life Sciences and Beckley Psytech to Combine …
5 days ago About atai Life Sciences atai is a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes. atai’s pipeline of psychedelic-based therapies … See details»
ATAI Life Sciences - Psychedelic Science Review
Dec 19, 2018 ATAI Life Sciences Its holdings’ foci range from drug discovery to drug development to enabling technologies, including novel administration methods and digital therapeutics tools. … See details»
atai Life Sciences - Crunchbase Investor Profile
Atai Life Sciences is a biotechnology company that develops therapies for mental health disorders. The company focuses on creating treatments using … See details»
atai Life Sciences - EverybodyWiki Bios & Wiki
Atai Life Sciences is a clinical-stage biopharmaceutical company that leverages alternative treatments for mental health disorders. Founded in 2018 and headquartered in Berlin, it has … See details»
ATAI LIFE SCIENCES | Flight Story
Atai Life Sciences, founded in 2018 by Florian Brand, Dr. Srinivas Rao, and Lars Wilde, is a clinical-stage biopharmaceutical company dedicated to transforming mental health treatment. Headquartered in Berlin, Germany, atai aims to … See details»
atai Life Sciences Reports First Quarter 2025 Financial - GlobeNewswire
May 14, 2025 ATAI LIFE SCIENCES N.V. CONDENSED CONSOLIDATED BALANCE SHEET (Amounts in thousands) March 31, December 31, 2025 2024 See details»
Atai Life Sciences, psychedelic startup Beckley Psytech plan merger
4 days ago Atai Life Sciences, among the most prominent biotechs focused on psychedelic medicines, said Monday it will merge with private psychedelic startup Beckley Psytech, pending … See details»
About - atai Life Sciences
You are now leaving atai Life Sciences’ website and entering a site that is not owned or controlled by atai. atai makes no representations regarding the accuracy of the information on external websites and does not endorse their … See details»
Investor relations | Atai Life Sciences N.V.
May 29, 2025 atai is a biopharmaceutical company developing new mental health treatments to transform patient outcomes.. Our research is focused on developing rapid-acting, robust and … See details»
our impact - atai Life Sciences
Atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, with offices in New York, San Diego and Berlin. Our vision is to heal … See details»
atai Life Sciences and Beckley Psytech Announce Strategic Merger to ...
4 days ago About atai Life Sciences atai is a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes. atai’s … See details»
Release details - ATAI Life Sciences N.V.
Feb 6, 2024 About atai Life Sciences atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders and was founded as a response to the … See details»
Mission and values - atai Life Sciences
Atai’s story Founded in 2018, atai emerged from the urgent need for better mental health solutions. Our founders, motivated by the struggles of their loved ones who faced limited treatment options, … See details»
atai Life Sciences Reports First Quarter 2025 Financial ... - BioSpace
May 14, 2025 About atai Life Sciences atai is a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes. Our … See details»
atai Life Sciences Reports First Quarter 2025 Financial Results and ...
May 14, 2025 About atai Life Sciences atai is a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes. Our … See details»
atai Life Sciences and Beckley Psytech to Combine Creating a Global ...
4 days ago NEW YORK and BERLIN and OXFORD, United Kingdom, June 02, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage … See details»
Optimizing atai Life Sciences’ Banking Structure to Drive Growth
Dec 1, 2024 In contrast, atai operates a decentralized platform approach to enable scalable drug or technological development at its atai companies (commonly known as a hub and spoke model). … See details»
atai Life Sciences Strengthens Leadership Team with Appointment of …
Nov 29, 2022 He also served as a market analyst for the World Health Organization and has co-founded a company building a drug delivery device focused on adherence. Dr. Kirpekar is a … See details»